References
- Meade T W., Haines A P., North W R S, Chakrabarti R, Howarth D J., Stirling Y. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg or 30 μg oestrogen. Lancet 1977; II: 948–51
- Böttiger L E., Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effect of lowering oestrogen content. Lancet 1980; 1: 1097–101
- Bergink E W., Borglin N E., Klottrup P, Liukko P. Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives and serum lipoproteins. Contraception 1982; 25: 477–85
- Wiseman A, Bowie J, Cogswell D, et al. Marvelon: clinical experience in the UK. Br J Fam Plann 1984; 10: 38–42
- Mattson L A., Cullberg G. Clinical and metabolic effects of Marvelon: Scandinavian experience. Br J Fam Plann 1984; 10: 42–7
- Weijers M J. Clinical trial of an oral contraceptive containing desogestrel and ethinylestradiol. Clin Ther 1982; 4: 359–66
- Mall-Haefeli Werner-Zodrow I., Huber P, Weijers M J. Klinische und biochemische Resultate bei der Behandlung mit Marvelon—einem neuen steroidalen Ovulationshemmer. Geburtshilfe Frauenheilkd 1982; 42: 3–18
- Bergink E W., Hamburger A D., de Jager E, van der Vies J. Binding of a contraceptive progestogen Org 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981; 14: 175–83
- Bergink E W., van Meel F, Turpijn E W., van der Vies J. Binding of progestogens to receptor proteins in MCF-7 cells. J Steroid Biochem 1983; 19: 1563–70
- Bound W, Vessey M, Wiggins P. A randomized double-blind trial of two low dose combined oral contraceptives. Br J Obstet Gynaecol 1979; 86: 325–9